地西他滨治疗骨髓增生异常综合征疗效分析.docVIP

地西他滨治疗骨髓增生异常综合征疗效分析 　　[摘要] 目的 探讨地西他滨治疗骨髓增生异常综合征的疗效。 方法 回顾性分析2012年5月～2015年5月我院收治的中、高危骨髓增生异常综合征患者63例，按照治疗方法将患者分为两组，研究组32例，对照组31例，两组在治疗期间均用相同的对症支持治疗。研究组用地西他滨治疗，对照组用传统的HA方案治疗（三尖杉酯碱及阿糖胞苷），治疗3个月后对比两组患者的临床疗效、不良反应发生率。 结果 研究组总有效率与对照组比较差异无统计学意义（P0.05），研究组不良反应总发生率与对照组比较明显较低，两组比较差异有统计学意义（P0.05）。 结论 地西他滨治疗骨髓增生异常综合征的疗效与HA方案相近，但不良反应总发生率较低，有较高的安全性，可作为一种适用骨髓增生异常综合征患者的治疗方法推荐使用。 　　[关键词] 骨髓增生异常综合征；中危；高危；地西他滨；疗效 　　[中图分类号] R551.3 [文献标识码] B [文章编号] 2095-0616（2015）18-185-03 　　[Abstract] Objective To study the curative effect of decitabine in the treatment of myelodysplastic syndrome. Methods 63 patients with medium，high risk myelodysplastic syndrome，who were received and cured in our hospital from May 2012 to May 2015，were retrospectively analyzed and divided into two groups which were treated with the same symptomatic supportive treatment during the treatment period，with 32 cases in study group and 31 cases in control group.To contrast the clinical effect and the incidence of adverse reaction after treatment 3 months between the two groups，while patients in study group were treated with decitabine， and patients in control group were treated with traditional HA regimen of harringtonine and cytarabine. Results The total effective rate between the two groups had little difference，there was no statistical significance（P0.05）.The overall incidence of adverse reaction in study group was obviously lower than which in control group，the difference was statistical significance（P0.05）. Conclusion Decitabine in the treatment of myelodysplastic syndrome has similar curative effect compared with HA regimen，but has lower overall incidence of adverse reaction，higher safety，could be recommended used as the treatment method on myelodysplastic syndrome. 　　[Key words] Myelodysplastic syndrome；Medium risk；High risk；Decitabine；Curative effect 　　骨髓增生异常综合征是一组起源于多能造血干细胞的恶性克隆性疾病[1]，以骨髓无效造血、长期的进行性难治性外周血细胞减少、造血功能衰竭等为主要特征表现，有向急性髓系白血病转化的风险，各年段均可发病，但中老年发病率较高，是对人类健康造成严重威胁的疾病之一[2]。临床多用免疫抑制剂、造血生长因子、诱导分化剂、雄激素等药物进行治疗，